

Agenda

Seminar on Availability of Veterinary Antimicrobials and Alternatives to their use

Place	LOOM AZCA, Plaza Pablo Ruiz Picasso, 11, Madrid, Spain
Time	October 15th, 2026
Organiser	PRAN - AEMPS (Spain)
Aim	- To highlight the work carried out by the Quadripartite initiative on availability of antimicrobials (AMs) and alternatives to their use (ATAMs) - To present the guidance on improving availability of AMs and ATAMs for EU therapeutic gaps - To discuss future actions on improving access to and availability of AMs and ATAMs
9:00 - 9:30	Opening remarks Cristina Muñoz, PRAN AEMPS, Spain
9:30 - 10:00	EU-JAMRAI2 initiatives to improve access (Online) Christine Ardal, FHI, Norway
10:00 - 10:30	Quadripartite initiative on availability of antimicrobials (AMs) and alternatives to their use (ATAMs) - Pilot project and guidance on availability of AM and ATAMs (Cristina Muñoz and Alejandro Platt, PRAN - AEMPS, Spain) - Discussion on outcomes and lessons learned (Quadripartite Members) - Questions and answers
10:30 - 11:00	EMA activities to prevent and manage shortages of medicinal products at EU level María Jesús Alcaraz Tomas, EMA, The Netherlands
11:00 - 11:30	FVE activities regarding the identification of therapeutic gaps Nancy De Briyne, FVE, Belgium
11:30 - 12:15	Coffee break
12:15 - 13:15	Improving access to and availability of AMs and ATAMs. Round Table Discussion: - Cristina Muñoz, PRAN – AEMPS, Spain - David Murphy, HPRA, Ireland - Maria João Costa Baptista Nabais, DGAV, Portugal - Nancy De Briyne, FVE, Belgium - Pablo Hervás Calle, Veterindustria, Spain - Miguel Ángel Higuera Pascual, ANPROGAPOR, Spain - Pachi Clemente Vicario, AVEPA, Spain - María Jesús Alcaraz Tomas, EMA, The Netherlands
13:15 - 13:30	Conclusions and next steps
13:30	Cocktail lunch

EU-JAMRAI2 receives funding from the European Union's EU4Health programme under grant agreement No 101127787. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.



**Co-funded by
the European Union**